SmithKline OTC switch strategy starting at Phase III after U.K. Tagamet switch failures.
This article was originally published in The Tan Sheet
Executive Summary
SMITHKLINE BEECHAM OTC SWITCH STRATEGIES STARTING IN PHASE III of Rx development: an internal switch team is beginning to formulate OTC strategies while medicines are still in their pre-approval clinical trials, SmithKline Beecham Switches Marketing Manager Mandy Johnson said at a conference on the European OTC marketplace in Amsterdam Sept. 29.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning